Slides
Page 1
JP MORGAN 46th ANNUAL HEALTHCARE CONFERENCE J A N U A R Y 1 4 , 2 0 2 6 ©2026 Myriad Genetics, Inc. Sam Raha PRESIDENT AND CEO
Page 2
Forward-looking statements and Non-GAAP financial measures 2 Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management’s current expectations and the actual events or results may differ materially and ad versely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and —are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research. The Company is in the process of finalizing its financial results for the quarter and full year ended December 31, 2025, and the financial guidance, data, and other information for the quarter and full year ended December 31, 2025 in this presentation is based on available information to d ate and is derived from preliminary, unaudited internal financial reports. This preliminary, unaudited financial information and data may change in connection with the finalization of the Company's year-end closing and reporting processes and financial statements for the quarter and full year ended December 31, 2025, and therefore, the financial guidance, data, and other information for the quarter and full year ended December 31, 2025 in this presentation may not represent the Company's actual financial results for the quarter and full year ended December 31, 2025. NON-GAAP FINANCIAL MEASURES In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results an d comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's con trol, or cannot be reasonably predicted at the time of this presentation. Such adjustments include, but are not limited to, strategic realignment, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and un predictable fluctuations in the Company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.
Page 3
We advance health and well-being for all, by providing testing solutions that enable healthcare providers to better prevent, detect, and treat disease 3
Page 4
Leveraging our strengths to chart the future of the new Myriad 1. Total number of providers having placed an order in 2025 1.5M+ patient tests reported in 2025 Leader in Molecular Diagnostic testing and Precision Medicine 1,000+ scientific publications 55K+ healthcare providers served in 20251 Reputation based on quality and science Sample processing and reporting operational excellence Commercial coverage and customer relationships Reimbursement engine Focused investments Cancer Care Continuum portfolio Strategic partnerships Right team Execution excellence Expanded AI leverage Strengths Going forward 4
Page 5
Healthcare Screening Drive Prenatal Health and Mental Health growth at or above market Cancer Care Continuum Accelerate growth with new products and expansion into attractive applications Execution Excellence Maintain disciplined focus on execution and sustained profitability Myriad’s strategic direction 5 Driving accelerated growth and profitability by focusing on the Cancer Care Continuum and strengthening execution
Page 6
Plan to leverage market leading positions and new products to accelerate growth Serving multiple large attractive markets 6 Sources: Definitive Healthcare 2024 Claims Data, Competitor earnings reports, 2025 Awareness, Trial, Usage Primary Market Research, ACS Cancer Facts & Figures 2025, GlobalData Epidemiology Database, Clarify 22/23 Claims Data, equity research reports, and Internal Estimates TAM ($Billions) Est. Annual Market Growth $2 7-10% AFFECTED HCT1 $5 9-12% UNAFFECTED HCT $1 12-15% PROSTATE BIOMARKER $8 14-17% THERAPY SELECTION; HRD & CGP2 $21 15-20% MRD3 $3 2-5% PRENATAL HEALTH $2 2-5% MENTAL HEALTH Risk and ScreeningPrecision Oncology 1. Hereditary Cancer Testing 2. Homologous Recombination Deficiency and Comprehensive Genomic Profiling 3. Molecular Residual Disease Top 3 Market Position Planned New Products Reflects position in HRD market only
Page 7
Hereditary cancer or multi-cancer early detection screening Monitoring & Therapy Adjustment Germline screening and tumor profiling Molecular Residual Disease testing Diagnosis & Therapy Selection Tumor profiling and CDx testing Germline screening Tumor profiling and CDx testing Molecular Residual Disease monitoring Expanding testing menu to serve more of the Cancer Care Continuum Risk & Early Detection Remission 1. Target launch H1 ‘26 2. Available for pharma use 7 MSK ACCESS 2 MSK ACCESS 2 1 1 1
Page 8
8 Cancer Care Continuum Portfolio Update
Page 9
• Launched MyRisk expanded panel; Q4 ’25 • Launch Disease Specific Panels; H1 ’26E • Expand Breast Cancer RiskScore to 365 SNPs3; H2 ’26E • Increase unaffected market activation HIGHLIGHTS Accelerating growth and gaining share in Hereditary Cancer 32% of women 25 or older meet criteria for HCT and 53% of these see change in medical management1,2 Guideline expansion and increasing clinical adoption 1. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023;20(9):902-914. doi:10.1016/j.jacr.2023.04.002 2. https://pubmed.ncbi.nlm.nih.gov/36906849/ 3. Single-nucleotide polymorphisms MyRisk expected to be a cornerstone of growth and profitability going forward Incorporates all genes strongly recommended in NCCN and ASCO guidelines 9 $5B 9-12% TAM EST. MARKET GROWTH $2B 7-10% UNAFFECTED HCT AFFECTED HCT MARKET DRIVERS
Page 10
Growing number of targeted therapies across cancer types are tied to therapy selection tests TAM EST. MARKET GROWTH $8B 14-17% THERAPY SELECTION; HRD & CGP Expanding offerings for Therapy Selection HRD 10 Tissue CGP Liquid CGP 1. Available for pharma use 2. Immuno-histochemistry HIGHLIGHTS Building towards a comprehensive Therapy Selection portfolio to support Precision Oncology • Expand HRD indications • Expand IHC2 offerings to complement Precise Tumor • Sophia Genetics / MSK partnership provides liquid biopsy CGP assay for Biopharma; option for clinical test MSK ACCESS1 MARKET DRIVER
Page 11
With over 60% of low-risk patients on Active Surveillance,2 AI tools have potential to more effectively guide clinical decisions Advancing prostate cancer testing with molecular and AI capabilities 11 Active surveillance Single-modal treatment Multi-modal treatment LOWER SCORE HIGHER SCORE 1 in 8 men in the US develop prostate cancer1 3M+ prostate cancer survivors HIGHLIGHTS • Launch first AI-enhanced Prolaris; H1 ’26E • Launch of second AI-enhanced Prolaris test planned for 2027 • Plan to progress clinical programs to strengthen NCCN guideline position Partnership with PATHOMIQ Uniquely positioned to deliver molecular + AI profiling, CGP and germline testing for prostate cancer care MARKET DRIVERS 1. National Cancer Institute (https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) 2. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801916#google_vignette
Page 12
TAM EST. ANNUAL MARKET GROWTH $21B 15-20% MOLECULAR RESIDUAL DISEASE TOTAL HIGHLIGHTS The combination of test performance, comprehensive portfolio, and leadership in community medicine will enable Myriad to grow a leading MRD business Growing market awareness of the importance of ultra- sensitive detection Community oncologist preference for comprehensive offering Entering MRD market with a differentiated approach 12 • Compliments Myriad’s portfolio of tests across the Cancer Care Continuum • Deploying dedicated MRD sales team targeting surgeons and oncologists • Numerous prospective and retrospective studies and publications underway Precise MRD is an ultra-sensitive, tissue informed assay that can detect ctDNA down to 1 part-per-million, enabling more confident clinical decision-making MRD INDICATIONS TAM $7B BREAST $5B CRC1 $1B RENAL $2B OVARIAN & ENDOMETRIAL MARKET DRIVERS 1. Colorectal cancer
Page 13
Growing MRD business through disciplined, phased launches 13 • Start clinical testing for select customers; H1 ’26E • Submit for MolDx review and launch early access; Q3 ’26E • Launch commercially; H1 ’27E PRECISE MRD FOR BREAST CANCER 2026E 2027E PRECISE MRD ROADMAP BEYOND BREAST • Renal cancer MolDx submission and early access launch; H2 • CRC MolDx submission and early access launch; H2 • Renal cancer commercial launch • CRC commercial launch • Endometrial cancer MolDx submission • Ovarian cancer MolDx submission • Medical Oncologist and Breast Surgeon experience • Targeted test volume and repeat orders TRACKING EARLY PROGRESS
Page 14
14 Prenatal Health and Mental Health Update
Page 15
HIGHLIGHTS Commercializing FirstGene expected to be a growth catalyst for Myriad • Encouraging early access experience for FirstGene • CONNECTOR study early results; H2 ‘26E • Commercial launch; H2 ’26E • Focused Prenatal Health sales team to deploy in H1 ’26 Expanding the Prenatal Heath market with FirstGene 1. Pereira et al, J Assist Reprod Genetics 2019 Apr; 36(4): 709-716 2. Arjunan et al, Prenat. Diagn. 2021 Jun; 41(7):896-90 Only 50% of US providers utilize carrier screening1 Only 30% of fathers get screened when mother is carrier2 Non-Invasive Prenatal Screening Carrier screening Fetal recessive status Blood compatibility Starting at 8-wk gestational age* * Estimated to begin in H2 ‘26 MARKET DRIVERS 15
Page 16
HIGHLIGHTS Genesight expected to achieve profitability over next few years with MSD growth and planned COGS reductions • Focus on high growth accounts • Leverage biomarker law momentum • Leverage digital engagement • Optimize direct-payment options Leading Mental Health testing with disciplined focus and execution 1 Mojtabai R, et al. J Clin Psychiatry. 2008 Jul;69(7):106574 2 https://www.fightcancer.org/what-we-do/access-biomarker-testing 3.https://journals.lww.com/psychopharmacology/fulltext/2025/07000/real_world_impact_of_pharmacogenomic_testing_on.3.aspx 1 in 5 Americans develop a major depressive disorder in their lifetime1 Positive biomarker testing coverage continues as 23 states have enacted legislation2 Provided over 3 million tests to date from 37,000+ providers 2025 published study showed those with major depressive disorder had fewer psychiatric hospitalizations after taking the GeneSight test3 MARKET DRIVERS 16
Page 17
17 Financial Update
Page 18
Preliminary Q4 and FY 2025 revenue Q4 2025E 2025E Total Revenue $207 - $209 $822 - $824 All figures in millions, except percentages 18 2025 COMMENTARY Total test volume growth of approximately 1% YOY reflecting: 7% Hereditary Cancer 6% Mental Health (4)% Prenatal Health
Page 19
19 Taking actions designed to drive strategic growth Investing in the Cancer Care Continuum Focus on driving commercial success Expansion of commercial organization Meaningful increase in field sales team Strengthen Sales Enablement Increase tools to support product launches, increase market activation spend Increase funding for strategic R&D programs Clinical studies for MRD and other select tests >$35M expected investment in commercial over the coming years 19
Page 20
$400 $700 $1,000 2025 2026E LRP Target All figures in millions 2026 FINANCIAL GUIDANCE 2026 COMMENTS Total Revenue $860 - 880 The mid-point of the 2026 revenue guidance range reflects an increase of approximately 6% compared to the mid-point of the preliminary 2025 revenue range. Adjusted Gross Margin* 68% - 69% This range incorporates the anticipated impact from new product launches Adjusted EBITDA* $37 - 49 The mid-point of the adjusted EBITDA range is expected to grow approximately 43% over the mid-point of the previous full year 2025 guidance range Introducing 2026 guidance and bridge to long range growth target * The company does not forecast GAAP gross margin and GAAP earnings before interest, tax, depreciation, or amortization (EBITDA) because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non- GAAP Financial Measures at the beginning of this presentation. All figures in millions except percentages Assumes currency rates as of January 14, 2026 Total Revenue High Single Digit – Low Double Digit % (Long-term CAGR) $860 - $880 20 $822 - $824 (Preliminary)
Page 21
• Initiate clinical testing for select customers; H1 • MolDx submissions for Breast (H1), Renal and CRC (H2) • Breast publication, MONITOR study; H2 • CRC data as part of pan-cancer publication, MONSTAR3 study; H2 Catalysts to watch in 2026E MRDHCT • Launch of MyRisk Disease Specific Panels; H1 • Increase sample volume growth rate Prostate Cancer • Launch Prolaris AI test; H1 • Prolaris meta-analysis publication; H2 • Increase sample volume growth • New strategic partnershipsCancer Care Continuum • Report out on FirstGene CONNECTOR study; H1 • Commercial launch of FirstGene; H2 Prenatal Health 21
Page 22
Strengthening execution excellence 22 New Myriad is set to deliver profitable accelerated growth Robust new product pipeline and strategic partnerships to address high growth markets Prioritized focus on the Cancer Care Continuum; Myriad has a right to win Extending commercial reach and leveraging operational strength Leadership team with domain knowledge and proven experience 22 4321 5 Annual revenue growth expected to accelerate to HSD to LDD% (long-term target)
Page 23
23 Q&A